Scilex Pharms Company Profile

What is the competitive landscape for SCILEX PHARMS

SCILEX PHARMS has three approved drugs.

There are twenty US patents protecting SCILEX PHARMS drugs.

There are sixty-three patent family members on SCILEX PHARMS drugs in twenty-five countries and two supplementary protection certificates in two countries.

Summary for Scilex Pharms

International Patents:	63
US Patents:	20
Tradenames:	3
Ingredients:	3
NDAs:	3

Drugs and US Patents for Scilex Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scilex Pharms	ZTLIDO	lidocaine	PATCH;TOPICAL	207962-001	Feb 28, 2018	AB	RX	Yes	Yes	9,283,174		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	10,376,527		Y
Scilex Pharms	ZTLIDO	lidocaine	PATCH;TOPICAL	207962-001	Feb 28, 2018	AB	RX	Yes	Yes	10,765,640		Y

International Patents for Scilex Pharms Drugs

Country	Patent Number	Estimated Expiration
Japan	6021269
European Patent Office	3363432
San Marino	T201800425

Supplementary Protection Certificates for Scilex Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925
0731795	10075033	Germany		PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Scilex Pharms

Pharmaceutical Competitive Landscape Analysis: Scilex Pharmaceuticals – Market Position, Strengths, and Strategic Insights

Last updated: February 12, 2026

What is Scilex Pharmaceuticals’ Position in the Market?

Scilex Pharmaceuticals (Nasdaq: SCLX) primarily operates in the pain management and dermatology sectors. Its product portfolio includes subcutaneous formulations, topical medications, and specialty drugs marketed for both acute and chronic conditions.

As of 2023, Scilex's approximate market share in the US pain management segment stands at 3-5%, according to IQVIA data. Its pipeline includes innovative formulations targeting neuropathic pain, post-surgical pain, and dermatology indications.

How Do Scilex’s Strengths Support Its Market Position?

Product Portfolio and Innovation

• Zevtera (SP-102): Approved for post-herpetic neuralgia, representing a novel sustained-release formulation of bupivacaine.
• SCS-01: An investigational NSAID topical gel addressing osteoarthritis pain.
• PRV-300: An investigational peptide for chronic pain, focusing on reducing systemic side effects.

Regulatory Strategy

• Scilex prioritizes efficient regulatory pathways, such as FDA's 505(b)(2), to accelerate product approvals.
• Zevtera received FDA approval in 2022, allowing early commercialization.

Strategic Collaborations and Licensing

• Partnership agreements with larger pharmaceutical firms for distribution and co-promotion bolster market reach.
• Licensing of technologies like sustained-release drug delivery expands product pipeline potential.

Financial and Operational Leverage

• As of Q2 2023, Scilex reported $70 million in quarterly revenue, with consistent growth rates.
• A lean operational structure reduces costs and improves agility compared to larger pharmaceutical entities.

What Are the Competitive Advantages and Challenges?

Competitive Advantages

• Focus on niche pain indications with unmet medical needs.
• Rapid product development cycle enabled by a streamlined R&D process.
• Growing patent portfolio securing exclusivity for key products through 2030.

Challenges

• Limited geographical footprint; primarily US-centric sales.
• Dependence on a small product portfolio exposes it to market volatility.
• Competition from larger firms like Purdue Pharma, Pfizer, and Teva, which have established market presence and broader pipelines.

What Are the Strategic Opportunities for Scilex?

Expansion of Product Pipeline

• Advancement of current pipeline leads, especially PRV-300, which could open new markets for chronic neuropathic pain.
• Development of biosimilar and generic formulations to capture additional market segments.

Geographic and Market Expansion

• Entry into European markets through partnerships or subsidiaries.
• Expansion into developing markets with unmet pain management needs, including Asia and Latin America.

M&A and Strategic Alliances

• Acquiring smaller biotech firms with complementary pain management candidates.
• Licensing innovative drug delivery platforms to accelerate pipeline development.

Technological Innovation

• Investment in drug delivery devices, such as sustained-release patches or implantable formulations.
• Engagement in biomarker development for personalized pain therapies.

What Does the Competitive Environment Look Like?

Company	Key Products	Market Share	Focus Area	Notable Moves
Purdue Pharma	OxyContin, Butrans	15-20%	Opioid and non-opioid pain meds	Bankruptcy (2021), transition to non-opioid focus
Pfizer	Lyrica, Celebrex	10-15%	Neuropathic pain, inflammation	Diversification into biologics
Teva	Austedo, Fentora	5-8%	Pain, neurological disorders	Focus on generics and biosimilars
Scilex	Zevtera, pipeline products	3-5%	Post-herpetic neuralgia, topical pain	Pipeline expansion, strategic licensing

What Are Key Takeaways for Stakeholders?

• Scilex’s niche focus on unmet pain management needs, especially in post-herpetic neuralgia, positions it favorably for growth.
• Its regulatory and development strategies facilitate faster market entry.
• Limited diversification and geographic scope pose risks; expansion efforts are critical.
• Competitive landscape remains intense, with larger firms leveraging broader portfolios and global reach.
• Strategic investments across pipeline, technology, and geographic markets could drive future valuation.

FAQs

1. What are Scilex’s main revenue-generating products?
   Zevtera (SP-102) is the primary product, generating significant revenue from post-herpetic neuralgia treatment.

2. What regulatory milestones are upcoming for Scilex?
   Formal NDA submission for PRV-300 is expected in Q4 2023, with potential approval by mid-2024.

3. How does Scilex plan to expand its pipeline?
   Through internal R&D and licensing deals, focusing on novel formulations for neuropathic and inflammatory pain.

4. What competitive threats does Scilex face?
   Larger firms with broader product lines and global distribution networks could outmarket Scilex’s niche products.

5. What strategic partnerships are significant for Scilex?
   Collaborations with distribution and biopharmaceutical companies enhance product reach and pipeline development.

References

1. IQVIA Institute. (2023). US Prescription Market Data.
2. Scilex Pharmaceuticals. (2023). Quarterly Earnings Report.
3. FDA. (2022). Approval Notices and Regulatory Frameworks.
4. Sector Analysis, Evaluate Pharma. (2023). Pain Management Market Trends.
5. Patent databases and company disclosures.